Divi's Labs Q3 PAT Falls 1% YoY; Revenue Up 12.1%

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAkshat Lakshkar|Published at:
Divi's Labs Q3 PAT Falls 1% YoY; Revenue Up 12.1%
Overview

Divi's Laboratories reported Q3 FY26 results showing a 12.1% YoY consolidated revenue growth to ₹2,692 crore. However, consolidated Profit After Tax (PAT) marginally declined 1% to ₹583 crore, impacted by a ₹74 crore exceptional item related to new Labour Codes. For nine months FY26, consolidated PAT surged 18.8% YoY to ₹1,817 crore on a 14.8% revenue increase. Standalone PAT saw minor growth in Q3 but strong 20% growth for nine months.

📉 The Financial Deep Dive

The Numbers:
Divi's Laboratories announced its Q3 FY26 financial results with a mixed performance. On a consolidated basis, total income grew by 12.1% year-on-year (YoY) to ₹2,692 crore. However, Profit After Tax (PAT) saw a marginal decline of 1% YoY, standing at ₹583 crore, compared to ₹589 crore in the previous year's corresponding quarter.

On a standalone basis, revenue from operations increased by 12.2% YoY to ₹2,578 crore. Standalone PAT grew marginally by 0.7% YoY to ₹598 crore from ₹594 crore.

For the nine-month period ended December 31, 2025 (9M FY26), the company demonstrated stronger growth. Consolidated total income rose 14.8% YoY to ₹8,081 crore, with PAT surging 18.8% YoY to ₹1,817 crore. Standalone PAT also saw robust growth of 20.0% YoY to ₹1,851 crore on a revenue increase of 14.0% YoY.

The Quality:
The Profit Before Tax (PBT) for Q3 FY26 on a consolidated basis grew 7.4% YoY to ₹780 crore, lagging behind the revenue growth. This indicates potential margin pressure or impact from an exceptional item of ₹74 crore, attributed to the incremental impact of employee benefits under new Labour Codes. Despite this, consolidated forex gains improved to ₹19 crore from ₹10 crore YoY, providing some buffer.

The Grill:
The provided filing does not contain management commentary from a conference call or specific guidance numbers. Therefore, insights into demand trends, analyst expectations vs. actual performance, or detailed strategy shifts are not available from this text alone.

🚩 Risks & Outlook

Specific Risks:
The primary risk highlighted is the impact of the ₹74 crore exceptional item related to new Labour Codes, which negatively affected Q3 profitability. The company operates in a single reportable segment (APIs, Intermediates, and Nutraceutical Ingredients), making it susceptible to specific market dynamics, raw material price fluctuations, and evolving regulatory landscapes in these sectors.

The Forward View:
While Q3 FY26 saw a slight dip in consolidated PAT due to cost impacts, the strong performance across the first nine months suggests underlying operational strength. Investors will closely monitor how Divi's Laboratories manages its cost structures, particularly the impact of the new Labour Codes, and its ability to translate revenue growth into improved profitability in the coming quarters. The company's agility in managing forex volatility and its position within the global API market will be key factors to watch.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.